Pharmcadd

PharmCADD is a drug discovery platform that combines quantum mechanics, molecular docking, molecular dynamics, and AI to predict protein structures and design new drug candidates. The company's Pharmulator platform uses AI, network theory, quantum calculation, and molecular dynamics to accelerate the drug discovery process. PharmCADD also develops PharmVAC, an mRNA vaccine platform designed to accelerate treatment effects on patients. The company is developing drugs targeting NAOC, cancer, Alzheimer's disease, and COVID-19, with active research in quantum computing applications for drug development through partnerships with organizations including MegazoneCloud. The platform has published research on molecular dynamics simulations of MEK1/2 kinase allosteric inhibitors and quantum mechanics-based molecular dynamics methodologies. Founded in 2019 and headquartered in Busan, South Korea, the company has raised $22.0M in Series B funding from investors including Huons, Samyang Holdings, SD Biosensor, Daily Partners, KTB Network, KBD Capital, Maple Investments, DSC Investment, KB Securities, and GNTech Venture Capital.